

Lung Cancer: The Times They Are a Changin'

- **James Lee, PhD** (Moderator)
 - Senior Consultant, Defined Health
- **Charles Rudin, MD, PhD**
 - Chief Thoracic Oncology, Sylvia Hassenfeld Chair in Lung Cancer Research, co-Director, Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
- **Maria Koehler, MD, PhD**
 - Vice President, Strategy, Innovation and Collaborations, Pfizer
- **Gregory Lubiniecki, MD**
 - Executive Director, Clinical Research Oncology, Merck Research Laboratories
- **Steve Worland, PhD**
 - President and Chief Executive Officer, eFFECTOR




**CANCER
PROGRESS**
by Defined Health

Cancer Progress by Defined Health
New York, NY | March 7 - 8, 2017

Immunotherapy will make up >50% of NSCLC WW Sales by 2022

Top 10 NSCLC Products by 2022 WW Sales




EvaluatePharma; includes products marketed and in development with consensus analyst forecasts

Cancer Progress by Defined Health
New York, NY | March 7 - 8, 2017

Although SCLC Accounts for ~15% of Lung Cancer, it Makes up <5% of 2022 WW Sales

NSCLC and SCLC WW Sales



EvaluatePharma; includes products marketed and in development with consensus analyst forecasts

Cancer Progress by Defined Health
New York, NY | March 7 - 8, 2017

Many Collaborations and Deals in Lung Cancer Since Beginning of Last Year

Incyte (INCY) And **AstraZeneca PLC** (AZN) Announce New Lung Cancer Clinical Trial Collaboration

Yuhan signs \$120 million license deal with China's Luoxin over lung cancer drug

Bristol-Myers, Bavarian Nordic test Opdivo-plus-vaccine combo in lung cancer

German Merck, Vaccinex ink lung cancer anti-PD-L1 combo trial deal

AbbVie and Bristol-Myers Squibb to collaborate on lung cancer clinical trial


G1 Therapeutics and Genentech to evaluate Phase II lung cancer trial of tecentriq and trilaciclib

Debiopharm teams up with Merck KGaA and Pfizer in lung cancer

Press release

Cancer Progress by Defined Health
New York, NY | March 7 - 8, 2017


Immunotherapy Approvals in NSCLC Came as a Pair this Past Year With More Expected



DH Research, Merck, BMS, Roche, AZ press release

Cancer Progress by Defined Health
 New York, NY | March 7 - 8, 2017

As a Result, Treatment of NSCLC has Changed Dramatically in the Past 2+ Years



NCCN, DH Research

Cancer Progress by Defined Health
 New York, NY | March 7 - 8, 2017

Panel Discussion Topics

- Future of Platinum Doublets
- Novel Monotherapy vs Combination Development
- Rational Combinations or Empirical Testing
- Predictive Biomarker Development
- Next Generation Targeted Therapies
- SCLC Future, Similar to NSCLC?